Introduction: Long-standing Misunderstandings of Gout

As early as the 5th century BC, Hippocrates, the father of Western medicine, documented a strange illness that mostly troubled wealthy men. Patients were jolted awake by severe foot joint pain at night, and he named it "the disease that makes walking impossible". Later, the ancient Roman physician Galen dissected swollen joints of gout patients and discovered white, tofu-like crystalline deposits under the skin. In 1848, British doctor Alfred Garrod confirmed that excessive uric acid was the core trigger of this illness, bringing gout into the framework of modern medical research. After more than 2,000 years of exploration, human understanding of gout has become increasingly comprehensive, yet a deep-rooted misconception still prevails: most people regard gout as nothing more than intermittent acute joint pain that fades away quickly.

According to the 2025 Guidelines for Anti-Inflammatory Treatment of Gout, gout is an inflammatory arthritis caused by monosodium urate crystal deposition. The prevalence among adults has reached 3.2% globally. Repeated gout attacks not only cause irreversible joint damage, but also sharply raise the risks of chronic kidney disease, cardiovascular disorders, diabetes and all-cause mortality. Every brief episode of joint pain is just an external signal of a long-term systemic chronic inflammation. Gout is never a temporary acute ailment; it is a persistent inflammatory condition that affects the whole body. In line with the national chronic disease management strategy, the medical community has reached a new consensus: effective gout treatment requires dual management of uric acid reduction and inflammation control, and neither can be neglected.

The Underestimated Hazard: Hidden Chronic Inflammation in Gout

Many gout patients inherit this condition from their families and follow a wrong treatment routine: taking medicine only when pain strikes and stopping all intervention once symptoms disappear. They only focus on fluctuating uric acid levels while ignoring the invisible chronic inflammation that continuously damages organs. Once urate crystals deposit in the body, they will trigger sustained inflammatory responses, which do not subside along with joint pain. Even during remission periods, inflammation remains active and silently harms the kidneys, blood vessels and other vital organs. This is why recurrent gout attacks lead to a series of severe complications.

Clinical experts have summarized three typical misconceptions among patients. First, prioritizing uric acid values over inflammation control. Many people only track uric acid test results and fail to realize that persistent inflammation is the root cause of long-term organ damage. Second, excessive fear of drug side effects, which makes them refuse long-term standardized medication. Third, treating a lifelong chronic disease as a sporadic acute illness. Worse still, many patients only start anti-inflammatory treatment when joint pain occurs, leading to incomplete and irregular therapy.

A large number of patients have encountered a typical dilemma: even when they stick to urate-lowering drugs, gout attacks become more frequent and severe. The underlying reason is that dissolved urate crystals stimulate intense inflammatory reactions in the body. This frustrating experience makes many patients resist regular medication. It fully proves that uric acid and inflammation interact closely and jointly determine the progression of gout. Simply controlling one factor cannot stop recurring attacks or improve patients' quality of life. Against this clinical backdrop, researchers are exploring new intervention methods that target inflammatory mechanisms fundamentally, providing new options for patients who cannot benefit from traditional treatment.

Against this backdrop, natural plant extracts with mild and reliable Cistanche benefits for the anti-inflammatory have gradually attracted attention from medical researchers and health product developers worldwide. Derived from traditional herbal medicine, Cistanche Tubulosa has been proven by modern pharmacological studies to relieve chronic inflammation, regulate metabolic balance and protect multiple organs, making it an ideal daily nutritional supplement for people suffering from hyperuricemia and gout.

New Landscape of Gout Treatment: Combine Uric Acid Reduction with Inflammation Control

With in-depth research on gout pathogenesis, the medical community has clarified that gout is not merely a metabolic disorder caused by purine imbalance and high uric acid, but a progressive inflammatory disease. Many patients keep their serum uric acid below 360 μmol/L with medication, yet joint inflammation still flares up repeatedly and eventually develops into chronic arthritis. This phenomenon clearly indicates that reaching the standard uric acid level cannot solve all problems.

Urate crystals continuously activate inflammatory pathways in the human body, and interleukin-1β (IL-1β) acts as a core medium to amplify inflammatory responses, resulting in persistent pain and tissue damage. In short, excessive uric acid initiates the disease, while chronic inflammation drives its deterioration. The 2025 Guidelines for Anti-Inflammatory Treatment of Gout has established a complete treatment framework: lowering uric acid and controlling inflammation must both reach the standard. The new treatment philosophy emphasizes systematic diagnosis, precise intervention and full-cycle disease management, and formulates hierarchical solutions based on attack frequency and comorbidities for individual patients.

The guidelines also sort out various anti-inflammatory therapies, including IL-1β targeted biological agents, and clarify their application scenarios in different disease stages. Meanwhile, medical staff pay more attention to practical clinical issues such as drug conversion, safety monitoring and medication for special groups, making treatment plans more scientific and operable.

The updated treatment concept brings three major changes to gout management. Firstly, comprehensive assessment: doctors evaluate not only uric acid levels, but also inflammatory indicators and recurrence risks. Secondly, extended treatment cycles: the management model shifts from emergency pain relief to long-term disease control. Thirdly, upgraded treatment goals: the core target changes from temporary symptom relief to blocking disease progression. With effective inflammation control, patients experience fewer attacks, regain the willingness to exercise, and maintain a healthy weight, which in turn stabilizes uric acid levels and forms a positive health cycle.

Innovative pharmaceutical preparations also support this new treatment strategy. New pre-filled injection drugs simplify administration procedures, avoid microbial contamination and dosage errors during preparation, and improve medication safety and compliance. As treatment concepts and products continue to advance, gout management is transforming from "relieving a single attack" to "long-term stable control". To promote this transformation on a larger scale, joint efforts from the medical industry and patients are indispensable.

From Individual Relief to Public Health: The Social Burden of Gout

Gout is no longer a personal health trouble. Its high incidence and younger onset trend have created a heavy social burden. Official statistics show that the standardized prevalence of hyperuricemia among adults is 13.3% to 17.7%, affecting approximately 180 million people globally, while the prevalence of gout ranges from 0.86% to 2.20%, with 11 million to 28 million diagnosed patients.

For individual patients, sudden gout attacks lead to frequent sick leave, reduced work efficiency and severe psychological anxiety. Many patients feel embarrassed when their condition is known by colleagues, and they dare not participate in social activities or outdoor sports for fear of triggering pain. In severe cases, swollen hands and feet make it impossible to wear shoes, and some young patients even lose the ability to work, bringing huge blows to individuals and families. Therefore, gout has been incorporated into the standardized chronic disease prevention and control system, focusing on early screening, pre-intervention and long-term precise management. People with elevated uric acid or recurrent joint swelling are advised to visit rheumatology departments or specialized gout clinics for professional assessment and long-term intervention.

To implement the dual management of uric acid reduction and inflammation control, medical professionals need to spread scientific cognition, and more safe and effective treatment options are required to help patients build confidence in long-term management. At present, therapies targeting inflammatory pathways play an increasingly important role. Stable inflammation control reduces attack frequency and complication risks. Moreover, chronic inflammation is also a key risk factor for hypertension, coronary heart disease and arteriosclerosis. Effective anti-inflammatory intervention can reduce long-term health hazards comprehensively. As a result, gout treatment is moving toward earlier intervention, more stable control and higher precision. The standardized management of gout, a once misunderstood disease, has become a replicable model for global chronic disease prevention and control.

Cistanche Tubulosa: Premium Natural Anti-Inflammatory Botanical Ingredient

Given the limitations of chemical drugs, including potential side effects and complicated administration, natural plant-based supplements have become a popular choice for daily inflammation regulation among global consumers. As a time-honored herbal ingredient, Cistanche Tubulosa stands out for its outstanding anti-inflammatory properties, and modern scientific research has fully verified its multiple mechanisms to relieve chronic inflammation related to gout.

Chengdu Wecistanche Bio-Tech Co., Ltd, founded in 2003, is the world's largest professional Cistanche Tubulosa processor with a registered capital of 10.3 billion RMB. Headquartered in Luopu County, Hotan, Xinjiang - the prime producing area of high-quality Cistanche Tubulosa, we have built a complete industrial chain covering 20,000 acres of seed breeding bases, over 85,000 acres of standardized cultivation bases and a GMP-certified deep processing factory. Our facility is equipped with a 100,000-class dust-free production workshop, a 10,000-class microbial laboratory and advanced ultrafiltration and nanofiltration purification equipment. We own 14 invention patents for cistanche extraction technology, and all products have obtained NOP, SOCA organic certification, HACCP, HALAL and Kosher certificates, fully complying with EU and U.S. food safety standards.

Different from ordinary Cistanche varieties, our Cistanche Tubulosa extract contains higher content of active ingredients including phenylethanoid glycosides, echinacoside and acteoside. Multiple in vitro and in vivo experiments have proven that these core components deliver remarkable anti-inflammatory effects by regulating multiple signaling pathways. They can effectively inhibit the activation of NF-κB and PI3K/AKT pathways, reduce the secretion of pro-inflammatory factors such as IL-1β, IL-6 and TNF-α, and suppress excessive production of nitric oxide (NO) and cyclooxygenase-2 (COX-2), which are closely linked to gout-related joint inflammation. Meanwhile, Cistanche Tubulosa extract can regulate gut microbiota structure, enrich beneficial bacteria, repair intestinal barriers and alleviate systemic inflammation triggered by metabolic disorders, forming a multi-dimensional protection for people with hyperuricemia and gout.

In addition to direct anti-inflammatory effects, our high-purity Cistanche Tubulosa extract also helps improve microcirculation and relieve oxidative stress, protecting kidneys and blood vessels from damage caused by long-term urate deposition and chronic inflammation. As a mild natural ingredient with thousands of years of application history, it has high safety and good absorption. Our extracts are widely supplied to global health food, dietary supplement and skincare manufacturers, and can be developed into capsules, oral liquids and other products for daily inflammation regulation and metabolic health care. Whether for people with mild hyperuricemia to prevent inflammation, or for gout patients to assist long-term chronic disease management, Cistanche Tubulosa is a reliable natural solution.

For decades, we have maintained long-term scientific research cooperation with Peking University School of Pharmacy, Shanghai Jiao Tong University School of Pharmacy and many renowned universities at home and abroad, led by Chief Scientist Professor Pengfei Tu, to continuously explore the pharmacological value of Cistanche Tubulosa. We also undertake social responsibilities such as desertification control and targeted poverty alleviation in Xinjiang, and donated a large number of cistanche products during the COVID-19 pandemic, winning wide recognition from the society. We always adhere to producing high-standard Cistanche Tubulosa extracts and deliver the natural power of this desert herb to global customers.

Buy Now

Supportive Service Of Wecistanche-For more details about cooperation

Email:Lijianlin@wecistanche.com

 

Disclaimer

This article is for science popularization and product promotion only. The anti-inflammatory effects of Cistanche Tubulosa are based on modern pharmacological research and traditional herbal application records. Our extracts are dietary supplement raw materials, not prescription drugs. They cannot replace professional medical treatment for gout and other inflammatory diseases. Please consult a professional doctor for diagnosis and treatment if you have physical discomfort.